Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481637 · ClinicalTrials.gov registry record
Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients
A clinical trial, sponsored by Rockefeller University.
- Completed
- Registry status
- 33
- Enrollment target
NCT00481637: Completed study, sponsored by Rockefeller University.
NCT00481637 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481637 has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to study whether immune cells capable of killing tumors that express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in small cell lung cancer and ovarian cancer patients. The presence of these cells may play a role in tumor immunity in these patients. The protocol involves neurological examinations and collection of blood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 1998-03 |
| Est. Completion | 2013-05 |
What the finished NCT00481637 record still lists
NCT00481637 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00481637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00481637 about?
NCT00481637 is a clinical study titled "Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients". The purpose of this study is to study whether immune cells capable of killing tumors that express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in small cell lung cancer and ovarian cancer patients. The presence of these cells may play a role in tumor immunity in the...
What is the current status of trial NCT00481637?
This trial is currently completed. The enrollment target is 33 participants. The study started on 1998-03. Estimated completion is 2013-05.
Who is sponsoring clinical trial NCT00481637?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia